Nikolaos Almyroudis

Nikolaos Almyroudis, MD, FACP

Roswell Park Cancer Institute
Assistant Professor
Department of Medicine
School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Assistant Professor of Medicine
Areas of Expertise: 
Infectious diseases
Special Interests: 
Infections in hematopoietic stem cell transplant recipients
Fungal infections and infections caused by resistant bacteria in patients with malignancies
Board Certification: 
Internal Medicine, American Board of Internal Medicine
Infectious Diseases, American Board of Internal Medicine
Fellowship: 
University of South Florida College of Medicine, Tampa, FL
Memorial Sloan-Kettering Cancer Center, New York, NY
Residency: 
Saint Savvas Oncology Hospital, Athens, Greece
University of Pittsburgh Medical Center (UPMC) Health System, McKeesport Hospital, McKeesport, PA
Education and Training: 
MD - Medical School of the National University of Athens, Athens, Greece
Publications
  • Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. Journal of supportive oncology 2012; 104:155-159
  • Jarkowski A 3rd, Forrest A, Sweeney RP, Tan W, Segal BH, Almyroudis N, Wang ES, Wetzler M.Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.Journal of oncology pharmacy practice 2012; 181:91-96
  • Almyroudis NG, Wetzler M, McCarthy PL Jr, Wang ES, Wongkittiroch K, Hazamy PA, Samonis G, Hahn T, Lesse AJ, Segal BH. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infection control and hospital epidemiology2011; 325:490-496
  • Grimm MJ, Robert Vethanayagam R, Almyroudis NG, Lewandowski D, Rall N, Blackwell TS, Segal BH.Role of NADPH oxidase in host defense against aspergillosis. Medical mycology 2011; 49Suppl. 1:S144-S149
  • Vethanayagam RR, Almyroudis NG, Grimm MJ, Lewandowski DC, Pham CT, Blackwell TS, Petraitiene R, Petraitis V, Walsh TJ, Urban CF, Segal BH. Role of NADPH oxidase versus neutrophil proteases in antimicrobial host defense. PloS one 2011; 612:e28149
  • Almyroudis NG , Segal BH. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert review of anti-infective therapy2010; 812:1451-1466
  • Partridge-Hinckley K, Liddell GM, Almyroudis NG, Segal BH. Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients. Mycopathologia 2009;1686:329-337
  • Almyroudis NG, Fabian J, Hahn T, Segal BH, Wetzler M, McCarthy Jr PL. Late infectious complications after cord blood stem cell transplantation. European journal of clinical microbiology and infectious diseases 2009; 2811:1405-1408
  • Almyroudis NG, Segal BH. Prevention and treatment of invasive fungal diseases in neutropenic patients. Current opinion in infectious diseases 2009; 224:385-393
  • Parameswaran GI, Segal BH, Almyroudis NG. Antifungal agents in hematopoietic stem cell transplantation. Current pharmaceutical design 2008; 1420:2011-2021
  • Gonzalez AV, Ullmann AJ, Almyroudis NG, Segal BH. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. Journal of the National Comprehensive Cancer Network : JNCCN 2008; 62:175-182
  • Segal BH, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, Baden LR, Graybill JR, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, De Pauw BE. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clinical infectious diseases2008; 475:674-683
  • Almyroudis NG, Clarke LA, Tucci VT, Greene JN, Vincent AL. Pseudomonas aeruginosa infections of cartilaginous structures. Asian biomedicine 2008; 25:361-369
  • Battiwalla M, Hahn T, Padmanabhan S, Nakamura R, Wallace PK, Segal BH, Almyroudis NG, Radovic M, Bajwa RP, Wu Y, McCarthy PL Jr. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biology of blood and marrow transplantation 2007; 137:765-770
  • Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrobial agents and chemotherapy 2007; 517:2587-2590
  • Battiwalla M, McCarthy PL, Becker J, Smith P, Elefante A, Abdelhalim A, McCarthy A, Almyroudis NG, Paplham P, Segal BH. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transplant infectious disease 2007; 91:28-32
  • Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, Wingard JR. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.Clinical infectious diseases 2007; 443:402-409
  • Gupta S, Kwon-Chung J, Varma A, Paplham P, Ball D, Proefrock AD, McCarthy PL, Bambach BJ, Battiwalla M, Almyroudis NG, Segal BH. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transplant infectious disease 2007; 92:156-160
  • Padmanabhan S, Battiwalla M, Hahn T, Ball D, Paplham P, Brown K, Segal BH, McCarthy P Jr, Almyroudis NG. Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature. Transplant infectious disease 2007; 92:148-152